All In Biotech

Drug Trial Radar · NCT07327034

ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression

A Randomized, Double-blind, Multi-center, Phase 2 Study to Assess the Efficacy and Safety of ABSK-011 Plus Best Supportive Care (BSC) vs. Placebo Plus BSC in Previously Systemically Treated Advanced or Unresectable Hepatocellular Carcinoma Patients With FGF19 Overexpression

Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 141 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

141

Planned (sponsor's estimate)

Start

Jun 13, 2025

Primary completion

Jun 30, 2027

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Abbisko Therapeutics Co, LtdIndustry
Sponsor type
Industry
First posted
Jan 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, multicenter, Phase 2 study to evaluate the efficacy and safety of ABSK-011 plus BSC versus placebo plus BSC in advanced or unresectable hepatocellular carcinoma (HCC) patients with FGF19 overexpression who have received prior systemic therapy. Approximately 141 advanced or unresectable HCC patients with FGF19 overexpression who have received prior systemic therapy will be enrolled and randomized to experimental arm or control arm in a 2:1 ratio. Patients will receive assigned study treatment, every 28-day treatment cycle within 1 day of randomization until disease progression, intolerable toxicity, start of new anti-tumor therapy, death, patient refuse to continue treatment, loss to follow-up, or other reasons leading to treatment discontinuation. Immediate BICR review is required for patients with radiographic disease progression as assessed by the investigator. If disease progression is assessed by BICR, the investigator is allowed to unblind after disease progression according to the protocol-specified procedures. After unblinding, patients in the experimental arm, study drug should be discontinued. Patients in the control arm may be transferred to receive ABSK-011 plus BSC after assessment.

Conditions

  • Hepatocellular Carcinoma (HCC)

Interventions

  • ABSK-011+BSCDrug

    ABSK-011 capsules will be provided and should be taken twice daily, with an interval of approximately 12 hours. The investigational product should be taken with food, with approximately 150 mL of water.

  • Placebo+BSCDrug

    Placebo capsules will be provided and should be taken twice daily, with an interval of approximately 12 hours. The investigational product should be taken with food, with approximately 150 mL of water.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORR by BICRTime frame: through study completion, up to 2 years

Locations

51 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, China · Recruiting

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China · Recruiting

  • The First Affiliated Hospital of USTC

    Hefei, Anhui, China · Recruiting

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China · Recruiting

  • Beijing Tsinghua Changgung Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Chongqing university cancer hospital

    Chongqing, Chongqing Municipality, China · Recruiting

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • The Second Affiliated Hospital of Guilin Medical University

    Guilin, Guangxi, China · Recruiting

  • Liuzhou People's Hospital

    Liuzhou, Guangxi, China · Recruiting

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, China · Recruiting

  • Guizhou Provincial People's Hospital

    Guiyang, Guizhou, China · Recruiting

  • Affiliated Cancer Hospital of Harbin Medical University

    Harbin, Heilongjiang, China · Recruiting

  • The First Affiliated Hospital of Henan University of Science & Technology

    Luoyang, Henan, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • Hubei Cancer Hospital

    Wuhan, Hubei, China · Recruiting

  • Tongji Hospital

    Wuhan, Hubei, China · Recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • General Hospital of Easten Theater Command

    Nanjing, Jiangsu, China · Not yet recruiting

  • Nanjing Tianyinshan Hospital

    Nanjing, Jiangsu, China · Recruiting

  • The First Affiliated Hospital with NanJing Medical University

    Nanjing, Jiangsu, China · Recruiting

  • Nantong Tumor Hospital

    Nantong, Jiangsu, China · Recruiting

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China · Recruiting

  • First Affiliated Hospital of Gannan Medical University

    Ganzhou, Jiangxi, China · Recruiting

  • Jiangxi Cancer Hospital

    Nanchang, Jiangxi, China · Recruiting

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • Jilin Cancer Hospital

    Changchun, Jilin, China · Recruiting

  • The First Hospital of Jilin University

    Changchun, Jilin, China · Recruiting

  • Liaoning Cancer Hospital

    Shenyang, Liaoning, China · Recruiting

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China · Recruiting

  • General Hospital of Ningxia Medical University

    Yinchuan, Ningxia, China · Recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong, China · Recruiting

  • Affiliated Hospital ofJining Medical University

    Jining, Shandong, China · Recruiting

  • Eastern hepatobilliary surgery hospital

    Shanghai, Shanghai Municipality, China · Not yet recruiting

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.